/
IFRX
$2.37+$0.36 (+18.75%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$282.8M
147M shares
52-week range
$0.74 – $2.95
74% from low
Exchange
NASDAQ
CS
Borrow rate
4.50%
Moderate
Price (6 mo)
Loading chart…
Change$-0.75
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $63.1K | $165.8K | $29.3K |
| Cost of revenue | $179.6K | $0 | $0 | $0 | $0 | $532.3K | $3.3M | $7.3M |
| Gross profit | −$179.6K | $0 | $0 | $0 | $0 | −$469.2K | −$3.2M | −$7.2M |
| Gross margin | — | — | — | — | — | -743.7% | -1900.8% | -24677.9% |
| R&D | $25.0M | $44.6M | $25.7M | $35.7M | $37.5M | $41.0M | $35.4M | $25.7M |
| Operating income | −$37.5M | −$56.8M | −$33.9M | −$47.6M | −$32.2M | −$44.6M | −$52.9M | −$48.3M |
| EBITDA | −$37.3M | −$56.5M | −$33.6M | −$44.9M | −$28.8M | −$42.1M | −$45.6M | −$45.2M |
| Net income | −$29.8M | −$53.3M | −$34.0M | −$45.6M | −$29.5M | −$42.7M | −$46.1M | −$45.6M |
| Net margin | — | — | — | — | — | -67630.7% | -27785.0% | -155582.1% |
| EPS (diluted) | -1.19 | -1.91 | -1.26 | -1.10 | -0.61 | -0.78 | -0.78 | -0.66 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $15449 | $-0.30 | $-0.33–$-0.27 | 4 |
| 2027 | $16233 | $-0.40 | $-0.48–$-0.32 | 3 |
| 2028 | $11629 | $-0.42 | $-0.82–$-0.20 | 1 |
| 2029 | $129M | $-0.17 | $-0.32–$-0.08 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.20
Price
$2.37
Implied downside
-92%
Peer comparison
InflaRx N.V. Common Stock
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
www.inflarx.de- Employees
- 65
- IPO / List date
- Nov 8, 2017
Held by traders on TradeandTell
No one on the platform currently holds IFRX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IFRX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IFRX yet.
